Seegene received Emergency Use Authorization from the US FDA for its Allplex HSV-1&2/VZV/MPXV multiplex real-time PCR assay. The test is intended to detect and differentiate herpes simplex virus type 1 and 2, varicella-zoster virus, and Mpox in ulcerative skin lesions. Seegene said the assay is designed for concurrent testing because similar vesicular or pustular presentations can cause diagnostic misses when clinicians test only one pathogen at a time. The company also highlighted that the assay uses multiple proprietary PCR technologies and its Seegene Digitalized Development System. The EUA marks an expansion of multiplex PCR capabilities into the US market via Seegene USA, supporting US clinical laboratories and public health needs. For labs and clinicians, the operational impact is a faster, single workflow approach to distinguishing among clinically overlapping causes of ulcerative lesions.